BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines bRUKINSA — United States Net Product Revenue ($M) ($M)
Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases
Latest, FY2023
946
Period ended Dec 31, 2023
Change on a year earlier
+142.6%
390 in FY2022
History
4 years
Since FY2020
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BRUKINSA — United States Net Product Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 946 | +142.6% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 390 | +236.8% | Form 10-K (filed 2023-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 116 | +535.7% | Form 10-K (filed 2022-02-28) ↗ |
| FY2020 | Dec 31, 2020 | 18.2 | – | Form 10-K (filed 2022-02-28) ↗ |
Breakdown
What makes up brukinsa — united states net product revenue ($m)
Cite this data
StockData. (2026). BeOne Medicines BRUKINSA — United States Net Product Revenue ($M) ($M), annual FY2020–FY2023 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_brukinsa_us
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.